Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres

British Journal of Pharmacology

Volumn 144, Issue 3, 2005, Pages 376-385

  Champeroux, Pascal ^a   Viaud, Karen ^a   El Amrani, Abdel Ilah ^a   Fowler, John Sinclair Lawrence ^b   Martel, Eric ^a   Le Guennec, Jean Yves ^c   Richard, Serge ^a  

^a CERB   (France)

^b Research and Liaison   (France)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

Drug safety; Proarrhythmic risk; Purkinje fibre; QT prolongation; Torsade de pointes

Indexed keywords

ACETYLSALICYLIC ACID; CHLOROQUINE; CIPROFLOXACIN; CISAPRIDE; CLARITHROMYCIN; CLOZAPINE; DIAZEPAM; DILTIAZEM; DOFETILIDE; DROPERIDOL; EMETINE; ERYTHROMYCIN; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; MOXIFLOXACIN; NICARDIPINE; OLANZAPINE; ONDANSETRON; PENTAMIDINE; PIMOZIDE; PROPAFENONE; PROPRANOLOL; RISPERIDONE; SERTINDOLE; SOTALOL; SPARFLOXACIN; TERFENADINE; THIORIDAZINE; UNINDEXED DRUG;

ACTION POTENTIAL; ALGORITHM; AMPLITUDE MODULATION; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DOG; DRUG SAFETY; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PURKINJE CELL; QT PROLONGATION; TORSADE DES POINTES;

ACTION POTENTIALS; ALGORITHMS; ANIMALS; ARRHYTHMIA; DOGS; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; MALE; MODELS, NEUROLOGICAL; PERFUSION; PURKINJE FIBERS; TORSADES DE POINTES;

EID: 14644397295     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706070     Document Type: Article

References (31)

1. ABINANDER, E.G. (1984). QT prolongation and torsade de pointes ventricular tachycardia produced by maprotiline. Am. J. Cardiol., 53, 654.
2. ANTZELEVITCH, C., SICOURI, S., LITOVSKY, S.H., LUKAS, A., KRISHNAN, S.C., DI DIEGO, J.M., GINTANT, G.A. & LIU, D.W. (1999a). Heterogeneity within the ventricular wall: electrophysiology and pharmacology of epicardial, endocardial and M cells. Circ. Res., 21, 45-61.
3. ANTZELEVITCH, C., SHIMIZU, W., YAN, G.X., SICOURI, S., WEISSENBURGER, J., NESTERENKO, V.V., BURASHNIKOV, A., DI DIEGO, J., SAFFITZ, J. & THOMAS, G.P. (1999b). The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J. Cardiovasc. Electrophysiol., 10, 1124-1152.
4. ARELLANO-RODRIGO, E., GARCIA, A., MONT, L. & ROQUE, M. (2001). Torsade de Pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome. Med. Clin. (Barc.)., 117, 118-119.
5. CHAMPEROUX, P., MARTEL, E., VANNIER, C., BLANC, V., LEGUENNEC, J.Y., FOWLER, J. & RICHARD, S. (2000). The preclinical assessment of the risk for QT interval prolongation. Therapie, 55, 101-109.
6. + channels IKR and IKS. Therapie, 55, 195-202.
7. DARPÖ, B. (2001). Spectrum of drugs prolonging QT interval and the incidence of torsade de pointes. Eur. Heart J. Suppl., 3, K70-K80.
8. DE ABAJO, F.J. & RODRIGUEZ, L.A.G. (1999). Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br. J. Clin. Pharmacol., 47, 307-313.
9. DEMAZIERE, J., FOURCADE, J.M., BUSSEUIL, C.T., ADELEINE, P., MEYER, S.M. & SAISSY, J.M. (1995). The hazards of chloroquine self prescription in west Africa. J. Toxicol. Clin. Toxicol., 33, 369-370.
10. DE PONTI, F., POLUZZI, E., CAVALLI, A., RECANATINI, M. & MONTANARO, N. (2002). Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf., 25, 263-286.
11. FABER, T.S., ZEHENDER, M. & JUST, H. (1994). Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf., 11, 463-476.
12. FROTHINGHAM, R. (2001). Rates of torsade de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifoloxacin, and moxifloxacin. Pharmacotherapy, 21, 1468-1472.
13. GLASSMAN, A.H. & BIGGER, J.T. (2001). Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry. 158, 1774-1782.
14. HADDAD, P.M. & ANDERSON, I.M. (2002). Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62, 1649-1671.
15. HII, J.T., WYSE, D.G., GILLIS, A.M., COHEN, J.M. & MITCHELL, L.B. (1991). Propafenone-induced torsade de pointes: cross-reactivity with quinidine. Pacing Clin. Electrophysiol., 14, 1568-1570.
16. HONDEGHEM, L.M. & HOFFMANN, P. (2003). Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependency and instability. J. Cardiovasc. Pharmacol., 41, 14-24.
17. KAMOCHI, H., NII, T., EGUCHI, K., MORI, T., YAMAMOTO, A., SHIMODA, K. & IBARAKI, K. (1999). Clarithromycin associated with torsade de pointes. Jpn. Circ. J., 63, 421-422.
18. LEMMENS-GRUBER, R., KARKHANEH, A., STUDENIK, C. & HEISTRACHER, P. (1996). Cardiotoxicity of emetine dihydrochloride by calcium channel blockade in isolated preparations and ventricular myocytes of guinea pig hearts. Br. J. Pharmacol., 117, 377-383.
19. LEMMENS-GRUBER, R., STUDENIK, C., KARKHANEH, A. & HEISTRACHER, P. (1997). Mechanism of sodium channel blockade in the cardiotoxic action of emetine dihydrochloride in isolated cardiac preparations and ventricular myocytes of guinea pigs. J. Cardiovasc. Pharmacol., 30, 554-561.
20. MALIK, M. & CAMM, A.J. (2001). Evaluation of drug-induced QT interval prolongation: implications for drug approval and labeling. Drug Saf., 24, 323-351.
21. MILBERG, P., ECKARDT, L., BRUNS, H.J., BIERTZ, J., RAMTIN, S., REINSCH, N., FLEISCHER, D., KIRCHHOF, P., FABRITZ, L., BREITHARDT, G. & HAVERKAMP, W. (2002). Divergent proarrythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early after-depolarizations and torsade de pointes. J. Pharmacol. Exp. Ther., 1, 218-225.
22. NONAKA, A., KASHIMOTO, S., IMAMURA, M., FURUYA, A. & KUMAZAWA, T. (1997). Mechanism of the negative inotropic effect of midazolam and diazepam in cultured foetal mouse cardiac myocytes. Eur. J. Anaesthesiol., 14, 481-487.
23. PACHER, P., UNGVARI, Z., NANASI, P.P., FURST, S. & KECSKEMETI, V. (1999). Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antipressants on their cardiac effects. Is there any? Curr. Med. Chem., 6, 469-480.
24. RAEHL, C.L., PATEL, A.K. & LEROY, M. (1985). Drug induced torsade de pointes. Clin. Pharm., 4, 675-690.
25. REDFERN, W.S., CARLSSON, L., DAVIS, A.S., LYNCH, W.G., MACKENZIE, I., PALETHORPE, S., SIEGL, P.K., STRANG, I., SULLIVAN, A.T., WALLIS, R., CAMM, A.J. & HAMMOND, T.G. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res., 58, 32-45.
26. ROSENGARTEN, M. & BROOKS, R. (1987). Torsade de pointes ventricular tachycardia in a hypothyroid patient treated with propafenone. Can. J. Cardiol., 3, 234-239.
27. SHIRAISHI, H., ISHIBASHI, K., URAO, N., HYOGO, M., TSUKAMOTO, M., KEIRA, N., HIRASAKI, S., SEO, Y., SHIRAYAMA, T. & NAKAGAWA, M. (2002). Two cases of polymorphic ventricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia. Intern. Med., 41, 445-448.
28. SINGH, B.N. (1992). Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. Am. J. Cardiol., 69, 68D-74D.
29. TZIVONI, D., KEREN, A., COHEN, A.M., LOEBEL, H., ZAHAVI, I., CHENZBRAUN, A. & STERN, S. (1984). Magnesium therapy for torsade de pointes. Am. J. Cardiol., 53, 528-530.
30. WARNER, B. & HOFFMANN, P. (2002). Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React. Toxicol. Rev., 21, 189-203.
31. WEBSTER, R., LEISHMAN, D. & WALKER, D. (2002). Towards a drug concentration effect relationship for QT prolongation and torsade de pointes. Initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. Curr. Opin. Drug Disc., 5, 116-126.